Compile Data Set for Download or QSAR
maximum 50k data
Found 276 with Last Name = 'connolly' and Initial = 'k'
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12066((3S)-3-({2-[4-(butan-2-yl)-3-methylphenoxy]benzene...)
Affinity DataKi:  100nM ΔG°:  -41.6kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12064((3S)-3-({2-[3-methyl-4-(propan-2-yl)phenoxy]benzen...)
Affinity DataKi:  110nM ΔG°:  -41.3kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12070((3S)-4-oxo-3-{[2-(4-phenylphenoxy)benzene]sulfonam...)
Affinity DataKi:  290nM ΔG°:  -38.8kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12062((3S)-4-oxo-3-({2-[3-(propan-2-yl)phenoxy]benzene}s...)
Affinity DataKi:  410nM ΔG°:  -37.9kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12058((3S)-3-{[2-(3-methylphenoxy)benzene]sulfonamido}-4...)
Affinity DataKi:  430nM ΔG°:  -37.8kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12067((3S)-4-oxo-3-({2-[4-(pentan-3-yl)phenoxy]benzene}s...)
Affinity DataKi:  440nM ΔG°:  -37.7kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12061((3S)-4-oxo-3-{[2-(3,4,5-trimethylphenoxy)benzene]s...)
Affinity DataKi:  450nM ΔG°:  -37.7kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12065((3S)-3-({2-[4-(butan-2-yl)phenoxy]benzene}sulfonam...)
Affinity DataKi:  490nM ΔG°:  -37.5kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12063((3S)-4-oxo-3-({2-[4-(propan-2-yl)phenoxy]benzene}s...)
Affinity DataKi:  620nM ΔG°:  -36.9kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12068((3S)-3-{[2-(4-cyclopentylphenoxy)benzene]sulfonami...)
Affinity DataKi:  880nM ΔG°:  -36.0kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12069((3S)-3-{[2-(4-cyclohexylphenoxy)benzene]sulfonamid...)
Affinity DataKi:  900nM ΔG°:  -35.9kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12060((3S)-3-{[2-(2,3-dimethylphenoxy)benzene]sulfonamid...)
Affinity DataKi:  1.00E+3nM ΔG°:  -35.6kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12059((3S)-3-{[2-(4-methylphenoxy)benzene]sulfonamido}-4...)
Affinity DataKi:  1.10E+3nM ΔG°:  -35.4kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12055((3S)-4-oxo-3-[(2-phenylbenzene)sulfonamido]butanoi...)
Affinity DataKi:  1.60E+3nM ΔG°:  -34.4kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12056((3S)-4-oxo-3-[(2-phenoxybenzene)sulfonamido]butano...)
Affinity DataKi:  2.40E+3nM ΔG°:  -33.4kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12057((3S)-3-{[2-(2-methylphenoxy)benzene]sulfonamido}-4...)
Affinity DataKi:  3.00E+3nM ΔG°:  -32.8kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCaspase-1(Homo sapiens (Human))
Pfizer

LigandPNGBDBM12071(4-[4-(2-{[(2S)-1-carboxy-3-oxopropan-2-yl]sulfamoy...)
Affinity DataKi:  4.20E+3nM ΔG°:  -31.9kJ/molepH: 7.0 T: 2°CAssay Description:The substrate peptides terminating in AMC are processed by caspases with or without inhibitors, and the accumulation of AMC was assessed with a Cytof...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Glaxo Wellcome Research

Curated by ChEMBL
LigandPNGBDBM50048241((3S,4S)-3-Acetyl-4-(3-cyclopentyloxy-4-methoxy-phe...)
Affinity DataKi:  7.90E+3nMAssay Description:Inhibition of human Phosphodiesterase 7More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Bos taurus)
Glaxo Wellcome Research

Curated by ChEMBL
LigandPNGBDBM50048241((3S,4S)-3-Acetyl-4-(3-cyclopentyloxy-4-methoxy-phe...)
Affinity DataKi: >1.00E+5nMAssay Description:Inhibition of bovine Phosphodiesterase 2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Glaxo Wellcome Research

Curated by ChEMBL
LigandPNGBDBM50048241((3S,4S)-3-Acetyl-4-(3-cyclopentyloxy-4-methoxy-phe...)
Affinity DataKi: >1.00E+5nMAssay Description:Inhibition of Phosphodiesterase 5 isolated from human tracheaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575601(CHEMBL4858933)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575593(CHEMBL4878832)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575590(CHEMBL4864361)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575588(CHEMBL4854038)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575591(CHEMBL4850183)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575600(CHEMBL4873487)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575587(CHEMBL4852516)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575599(CHEMBL4848140)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575592(CHEMBL4860917)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575586(CHEMBL4848442)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575589(CHEMBL4877684)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575568(CHEMBL4870385)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575604(CHEMBL4873956)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575596(CHEMBL4848114)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575597(CHEMBL4861509)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575579(CHEMBL4847817)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575565(CHEMBL4864280)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575576(CHEMBL4874906)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575606(CHEMBL4856040)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575595(CHEMBL4849766)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462705(US10780090, Compound I-43 | {(1R,2S,4R)-4-[(5-{[4-...)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575605(CHEMBL4865157)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462958(US10780090, Compound I-263a | US10780090, Compound...)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575575(CHEMBL4870143)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575555(CHEMBL4878088)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575570(CHEMBL4865787)
Affinity DataIC50:  1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 276 total ) | Next | Last >>
Jump to: